Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.

Casolari DA, Nguyen T, Butcher CM, Iarossi DG, Hahn CN, Bray SC, Neufing P, Parker WT, Feng J, Maung KZY, Wee A, Vidovic L, Kok CH, Bardy PG, Branford S, Lewis ID, Lane SW, Scott HS, Ross DM, D'Andrea RJ.

Sci Rep. 2017 May 26;7(1):2467. doi: 10.1038/s41598-017-02655-7.

2.

RUNX1 mutations are rare in chronic phase polycythaemia vera.

Butcher CM, Neufing PJ, Eriksson L, Carmichael CL, Wilkins EJ, Melo JV, Lewis ID, Bardy PG, Scott HS, D'Andrea RJ.

Br J Haematol. 2011 Jun;153(5):672-5. doi: 10.1111/j.1365-2141.2011.08589.x. Epub 2011 Feb 20. No abstract available.

PMID:
21332713
3.

Different temporal expression of immunodominant Ro60/60 kDa-SSA and La/SSB apotopes.

Reed JH, Neufing PJ, Jackson MW, Clancy RM, Macardle PJ, Buyon JP, Gordon TP.

Clin Exp Immunol. 2007 Apr;148(1):153-60.

4.

Changes in steroid receptors and proteoglycan expression in the guinea pig prostate stroma during puberty and hormone manipulation.

Sakko AJ, Ricciardelli C, Mayne K, Dours-Zimmermann MT, Zimmermann DR, Neufing P, Tilley WD, Marshall VR, Horsfall DJ.

Prostate. 2007 Feb 15;67(3):288-300.

PMID:
17192879
5.

Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block.

Clancy RM, Neufing PJ, Zheng P, O'Mahony M, Nimmerjahn F, Gordon TP, Buyon JP.

J Clin Invest. 2006 Sep;116(9):2413-22. Epub 2006 Aug 10.

6.

Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.

Severi G, Hayes VM, Neufing P, Padilla EJ, Tilley WD, Eggleton SA, Morris HA, English DR, Southey MC, Hopper JL, Sutherland RL, Boyle P, Giles GG.

Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1142-7.

7.

Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant.

Butler LM, Centenera MM, Neufing PJ, Buchanan G, Choong CS, Ricciardelli C, Saint K, Lee M, Ochnik A, Yang M, Brown MP, Tilley WD.

Mol Endocrinol. 2006 May;20(5):1009-24. Epub 2006 Jan 19.

PMID:
16423882
8.

Exposure and binding of selected immunodominant La/SSB epitopes on human apoptotic cells.

Neufing PJ, Clancy RM, Jackson MW, Tran HB, Buyon JP, Gordon TP.

Arthritis Rheum. 2005 Dec;52(12):3934-42.

9.

A functional autoantibody in narcolepsy.

Smith AJ, Jackson MW, Neufing P, McEvoy RD, Gordon TP.

Lancet. 2004 Dec 11-17;364(9451):2122-4.

PMID:
15589310
10.

Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.

Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, Marshall VR, Horsfall DJ, Tilley WD.

Prostate. 2005 Apr 1;63(1):19-28.

PMID:
15378523
11.

ICA69 autoantibodies in primary Sjögren's syndrome.

Gordon TP, Cavill D, Neufing P, Zhang YJ, Pietropaolo M.

Lupus. 2004;13(6):483-4. No abstract available.

PMID:
15303579
12.

Structural and functional consequences of glutamine tract variation in the androgen receptor.

Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufing PJ, Coetzee GA, Tilley WD.

Hum Mol Genet. 2004 Aug 15;13(16):1677-92. Epub 2004 Jun 15.

PMID:
15198988
13.

Expression and localization of homeodomain proteins DLX4, HB9 and HB24 in malignant and benign human colorectal tissues.

Hollington P, Neufing P, Kalionis B, Waring P, Bentel J, Wattchow D, Tilley WD.

Anticancer Res. 2004 Mar-Apr;24(2B):955-62.

14.

Apolipoprotein-D: a novel cellular marker for HGPIN and prostate cancer.

Hall RE, Horsfall DJ, Stahl J, Vivekanandan S, Ricciardelli C, Stapleton AM, Scardino PT, Neufing P, Tilley WD.

Prostate. 2004 Feb 1;58(2):103-8.

PMID:
14716735
15.

Expression and localization of homeodomain proteins DLX4/HB9 in normal and malignant human breast tissues.

Neufing PJ, Kalionis B, Horsfall DJ, Ricciardelli C, Stahl J, Vivekanandan S, Raymond W, Tilley WD.

Anticancer Res. 2003 Mar-Apr;23(2B):1479-88.

PMID:
12820413
16.

ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer.

Severi G, Giles GG, Southey MC, Tesoriero A, Tilley W, Neufing P, Morris H, English DR, McCredie MR, Boyle P, Hopper JL.

J Natl Cancer Inst. 2003 Jun 4;95(11):818-24.

PMID:
12783937
17.

Establishing lysogenic transcription in the temperate coliphage 186.

Neufing PJ, Shearwin KE, Egan JB.

J Bacteriol. 2001 Apr;183(7):2376-9.

18.

The CII protein of bacteriophage 186 establishes lysogeny by activating a promoter upstream of the lysogenic promoter.

Neufing PJ, Shearwin KE, Camerotto J, Egan JB.

Mol Microbiol. 1996 Aug;21(4):751-61.

PMID:
8878038

Supplemental Content

Loading ...
Support Center